Occult HBV infection

[1]  P. Sogni,et al.  Hepatitis B and human immunodeficiency virus co-infection. , 2014, World journal of gastroenterology.

[2]  M. Yuen,et al.  Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  G. Raimondo,et al.  Hepatitis B virus and hepatitis C virus dual infection. , 2014, World journal of gastroenterology.

[4]  H. Marusawa,et al.  Reactivation from occult HBV carrier status is characterized by low genetic heterogeneity with the wild-type or G1896A variant prevalence. , 2014, Journal of hepatology.

[5]  G. Raimondo,et al.  Occult hepatitis B infection. , 2014, Journal of hepatology.

[6]  G. Raimondo,et al.  Hepatitis B virus PreS/S gene variants: pathobiology and clinical implications. , 2014, Journal of hepatology.

[7]  S. Boccia,et al.  HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF-α) Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis , 2014, International journal of rheumatology.

[8]  G. Raimondo,et al.  Therapy of Occult Hepatitis B Virus Infection and Prevention of Reactivation , 2014, Intervirology.

[9]  C. Saitta,et al.  Occult hepatitis B virus and hepatocellular carcinoma. , 2014, World journal of gastroenterology.

[10]  A. Lok,et al.  Management of patients with hepatitis B who require immunosuppressive therapy , 2014, Nature Reviews Gastroenterology &Hepatology.

[11]  T. Liang,et al.  Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA , 2014, Science.

[12]  Xiaohong Wang,et al.  Complete replication of hepatitis B virus and hepatitis C virus in a newly developed hepatoma cell line , 2014, Proceedings of the National Academy of Sciences.

[13]  F. Hollinger,et al.  Occult hepatitis B virus infection and hepatocellular carcinoma: a systematic review , 2014, Journal of viral hepatitis.

[14]  R. Purcell,et al.  Limited Hepatitis B Virus Replication Space in the Chronically Hepatitis C Virus-Infected Liver , 2014, Journal of Virology.

[15]  Y. Louzoun,et al.  HBsAg genetic elements critical for immune escape correlates with HBV reactivation upon immunosuppression , 2014 .

[16]  Chien-Jen Chen,et al.  Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma , 2013, Gut.

[17]  M. Mitka.  FDA: Increased HBV reactivation risk with ofatumumab or rituximab. , 2013, JAMA.

[18]  Mengji Lu,et al.  Regulation of hepatitis B virus replication by epigenetic mechanisms and microRNAs , 2013, Front. Genet..

[19]  A. Alibrandi,et al.  Impact of occult hepatitis B virus infection on the outcome of chronic hepatitis C. , 2013, Journal of hepatology.

[20]  Wenhui Li,et al.  Alpha-Interferon Suppresses Hepadnavirus Transcription by Altering Epigenetic Modification of cccDNA Minichromosomes , 2013, PLoS pathogens.

[21]  G. Altavilla,et al.  Risk of occult hepatitis B virus infection reactivation in patients with solid tumours undergoing chemotherapy. , 2013, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[22]  Shou-Dong Lee,et al.  Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  T. Yeh,et al.  Occult and Overt HBV Co-Infections Independently Predict Postoperative Prognosis in HCV-Associated Hepatocellular Carcinoma , 2013, PloS one.

[24]  C. Shin,et al.  c‐Myc‐mediated overexpression of miR‐17‐92 suppresses replication of hepatitis B virus in human hepatoma cells , 2013, Journal of medical virology.

[25]  J. Allain,et al.  Specific Amino Acid Substitutions in the S Protein Prevent Its Excretion In Vitro and May Contribute to Occult Hepatitis B Virus Infection , 2013, Journal of Virology.

[26]  Xiang-Dong Fu,et al.  Hepatitis B Viral RNA Directly Mediates Down-regulation of the Tumor Suppressor MicroRNA miR-15a/miR-16-1 in Hepatocytes* , 2013, The Journal of Biological Chemistry.

[27]  O. Shibolet,et al.  Immunosuppression and HBV Reactivation , 2013, Seminars in Liver Disease.

[28]  Alessandro Nanni Costa,et al.  Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: evidence from the Liver Match cohort study. , 2013, Journal of hepatology.

[29]  L. Covolo,et al.  Occult hepatitis B virus and the risk for chronic liver disease: a meta-analysis. , 2013, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[30]  K. Morris,et al.  Snapshots: chromatin control of viral infection. , 2013, Virology.

[31]  W. Yeo,et al.  Hepatitis B virus reactivation associated with anti‐neoplastic therapy , 2013, Journal of gastroenterology and hepatology.

[32]  N. Yesilot,et al.  No detection of occult HBV-DNA in patients with various rheumatic diseases treated with anti-TNF agents: a two-year prospective study. , 2013 .

[33]  S. Bae,et al.  Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. , 2013, Clinical and experimental rheumatology.

[34]  G. Raimondo,et al.  Hepatitis B virus DNA integration in tumour tissue of a non-cirrhotic HFE-haemochromatosis patient with hepatocellular carcinoma. , 2013, Journal of hepatology.

[35]  Jinhong Chang,et al.  The innate immune response to hepatitis B virus infection: implications for pathogenesis and therapy. , 2012, Antiviral research.

[36]  S. Yeh,et al.  Influence of mutations in hepatitis B virus surface protein on viral antigenicity and phenotype in occult HBV strains from blood donors. , 2012, Journal of hepatology.

[37]  Christina Leslie,et al.  An atlas of the Epstein-Barr virus transcriptome and epigenome reveals host-virus regulatory interactions. , 2012, Cell host & microbe.

[38]  A. Alibrandi,et al.  Impact of hepatitis B virus (HBV) preS/S genomic variability on HBV surface antigen and HBV DNA serum levels , 2012, Hepatology.

[39]  C. M. Martin,et al.  Mutations associated with occult hepatitis B virus infection result in decreased surface antigen expression in vitro , 2012, Journal of viral hepatitis.

[40]  J. Allain,et al.  Hepatitis B virus in transfusion medicine: still a problem? , 2012, Biologicals : journal of the International Association of Biological Standardization.

[41]  M. Levrero,et al.  Transcriptional regulation of miR-224 upregulated in human HCCs by NFκB inflammatory pathways. , 2012, Journal of Hepatology.

[42]  S. Sauleda,et al.  T cell responses and viral variability in blood donation candidates with occult hepatitis B infection. , 2012, Journal of hepatology.

[43]  Y. Li,et al.  MicroRNA-141 Represses HBV Replication by Targeting PPARA , 2012, PloS one.

[44]  Wei Wu,et al.  Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta‐analysis , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[45]  M. Levrero,et al.  IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. , 2012, The Journal of clinical investigation.

[46]  C. Lin,et al.  Occult hepatitis B infection in blood donors from South East Asia: molecular characterisation and potential mechanisms of occurrence , 2012, Gut.

[47]  M. Buendia,et al.  Inhibition of PP1 Phosphatase Activity by HBx: A Mechanism for the Activation of Hepatitis B Virus Transcription , 2012, Science Signaling.

[48]  J. Samal,et al.  Molecular Mechanisms Underlying Occult Hepatitis B Virus Infection , 2012, Clinical Microbiology Reviews.

[49]  Valentina Svicher,et al.  Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. , 2012, Antiviral research.

[50]  J. Allain,et al.  Challenges in hepatitis B detection among blood donors , 2011, Current opinion in hematology.

[51]  E. Sagnelli,et al.  Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings , 2011, Journal of medical virology.

[52]  I. Hung,et al.  Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma , 2011, Hepatology.

[53]  G. Raimondo,et al.  Hepatocellular carcinoma: the point of view of the hepatitis B virus. , 2011, Carcinogenesis.

[54]  Tomasz P. Michalak,et al.  Hepatitis B virus quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy , 2011, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[55]  Z. Tian,et al.  Ectopic expression of microRNA-155 enhances innate antiviral immunity against HBV infection in human hepatoma cells , 2011, Virology Journal.

[56]  S. Belknap,et al.  Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[57]  Chien-Jen Chen,et al.  Hepatitis B virus infection and risk of intrahepatic cholangiocarcinoma and non‐Hodgkin lymphoma: A cohort study of parous women in Taiwan , 2011, Hepatology.

[58]  Francesca Zerbini,et al.  Human microRNA hsa-miR-125a-5p interferes with expression of hepatitis B virus surface antigen , 2011, Nucleic acids research.

[59]  Roger Y Dodd,et al.  Nucleic acid testing to detect HBV infection in blood donors. , 2011, The New England journal of medicine.

[60]  F. Zoulim,et al.  Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT , 2011, Bone Marrow Transplantation.

[61]  S. Zeuzem,et al.  EASL Clinical Practice Guidelines: management of hepatitis C virus infection. , 2011, Journal of hepatology.

[62]  K. Man,et al.  Occult hepatitis B virus infection of donor and recipient origin after liver transplantation despite nucleoside analogue prophylaxis , 2010, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[63]  R. Crowther,et al.  Impact of hepatitis B virus surface protein mutations on the diagnosis of occult hepatitis B virus infection , 2010, Hepatology.

[64]  Xin Li,et al.  Suppression of hepatitis B virus replication by microRNA-199a-3p and microRNA-210. , 2010, Antiviral research.

[65]  A. Oshima,et al.  Risk factors for intrahepatic cholangiocarcinoma: a possible role of hepatitis B virus , 2010, Journal of viral hepatitis.

[66]  Z. Herceg,et al.  DNA methylation of hepatitis B virus (HBV) genome associated with the development of hepatocellular carcinoma and occult HBV infection. , 2010, The Journal of infectious diseases.

[67]  M. Manns,et al.  Managing HBV in patients with impaired immunity , 2010, Gut.

[68]  T. Günther,et al.  The Epigenetic Landscape of Latent Kaposi Sarcoma-Associated Herpesvirus Genomes , 2010, PLoS pathogens.

[69]  V. Mazzaferro,et al.  Massive APOBEC3 Editing of Hepatitis B Viral DNA in Cirrhosis , 2010, PLoS pathogens.

[70]  Sarman Singh,et al.  Occult Hepatitis B Virus infection in ART-Naive HIV-Infected Patients seen at a Tertiary Care Centre in North India , 2010, BMC infectious diseases.

[71]  J. Minárovits,et al.  Epigenetic regulation of latent Epstein-Barr virus promoters. , 2010, Biochimica et biophysica acta.

[72]  D. Bloom,et al.  Epigenetic regulation of latent HSV-1 gene expression. , 2010, Biochimica et biophysica acta.

[73]  A. Unal,et al.  Occult HBV Infection in Continuous Ambulatory Peritoneal Dialysis and Hemodialysis Patients , 2010, Renal failure.

[74]  A. Burroughs,et al.  Liver grafts from anti-hepatitis B core positive donors: a systematic review. , 2010, Journal of hepatology.

[75]  F. Hollinger,et al.  Occult hepatitis B virus infection: a covert operation , 2010, Journal of viral hepatitis.

[76]  F. Zoulim,et al.  Control of hepatitis B virus replication by innate response of HepaRG cells , 2010, Hepatology.

[77]  Chien-Hung Chen,et al.  Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients , 2010, Annals of Hematology.

[78]  M. Buti,et al.  Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab. , 2009, Journal of hepatology.

[79]  M. Levrero,et al.  Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function , 2009, Proceedings of the National Academy of Sciences.

[80]  E. Jaffe,et al.  Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report , 2009, Haematologica.

[81]  O. Guillaud,et al.  Close monitoring of serum HBV DNA levels and liver enzymes levels is most useful in the management of patients with occult HBV infection. , 2009, Journal of hepatology.

[82]  J. Allain,et al.  Transfusion-transmitted hepatitis B virus infection. , 2009, Journal of hepatology.

[83]  M. Levrero,et al.  Control of cccDNA function in hepatitis B virus infection. , 2009, Journal of hepatology.

[84]  C. M. Martin,et al.  Cytokine expression during chronic versus occult hepatitis B virus infection in HIV co-infected individuals. , 2009, Cytokine.

[85]  S. Locarnini,et al.  Hepatitis B virus and hepatitis C virus interaction in Huh-7 cells. , 2009, Journal of hepatology.

[86]  Chien-Jen Chen,et al.  Hepatitis B virus infection and hepatocellular carcinoma among parous Taiwanese women: nationwide cohort study. , 2009, Journal of the National Cancer Institute.

[87]  C. Sureau,et al.  A Function Essential to Viral Entry Underlies the Hepatitis B Virus “a” Determinant , 2009, Journal of Virology.

[88]  R. Bartenschlager,et al.  Hepatitis B and C virus coinfection: A novel model system reveals the absence of direct viral interference , 2009, Hepatology.

[89]  R. Ueda,et al.  Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma , 2009, International journal of hematology.

[90]  A. Tamori,et al.  Frequent detection of hepatitis B virus DNA in hepatocellular carcinoma of patients with sustained virologic response for hepatitis C virus , 2009, Journal of medical virology.

[91]  M. Vermeulen,et al.  Characterization of occult hepatitis B virus strains in south african blood donors , 2009, Hepatology.

[92]  L. Gesualdo,et al.  Occult HBV infection in hemodialysis setting is marked by presence of isolated antibodies to HBcAg and HCV. , 2009, Journal of nephrology.

[93]  X. Teng,et al.  Molecular characterization and functional analysis of occult hepatitis B virus infection in Chinese patients infected with genotype C , 2009, Journal of medical virology.

[94]  M. Torbenson,et al.  Methylation regulates hepatitis B viral protein expression. , 2009, The Journal of infectious diseases.

[95]  C. Boucher,et al.  Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy , 2009, Journal of medical virology.

[96]  E. Rigopoulou,et al.  Occult hepatitis B virus infection in patients with autoimmune liver diseases , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[97]  C. Avellini,et al.  Occult hepatitis B virus infection in liver transplant recipients with recurrent hepatitis C: relationship with donor age and fibrosis progression , 2009, Clinical transplantation.

[98]  Edwin P Hui,et al.  Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[99]  D. Rossi,et al.  Occult hepatitis B virus infection of peripheral blood mononuclear cells among treatment-naïve patients with chronic lymphocytic leukemia , 2009, Leukemia & lymphoma.

[100]  Jörg Petersen,et al.  EASL Clinical Practice Guidelines: management of chronic hepatitis B. , 2009, Journal of hepatology.

[101]  M. Buendia,et al.  Statements from the Taormina expert meeting on occult hepatitis B virus infection. , 2008, Journal of hepatology.

[102]  I. Hung,et al.  HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. , 2008, Gastroenterology.

[103]  Michael Schmidt,et al.  Characterization of occult hepatitis B virus from blood donors carrying genotype A2 or genotype D strains. , 2008, Journal of hepatology.

[104]  P. Lieberman.  Chromatin organization and virus gene expression , 2008, Journal of cellular physiology.

[105]  J. Greeve,et al.  Hepatitis B: modern concepts in pathogenesis – APOBEC3 cytidine deaminases as effectors in innate immunity against the hepatitis B virus , 2008, Current opinion in infectious diseases.

[106]  F. Hollinger.  Hepatitis B virus infection and transfusion medicine: science and the occult , 2008, Transfusion.

[107]  G. Missale,et al.  The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. , 2008, Gastroenterology.

[108]  S. Mondello,et al.  Occult hepatitis B virus in liver tissue of individuals without hepatic disease. , 2008, Journal of hepatology.

[109]  G. Sommer,et al.  Posttranscriptional control of HBV gene expression. , 2008, Frontiers in bioscience : a journal and virtual library.

[110]  S. Ray,et al.  Comprehensive genetic and epigenetic analysis of occult hepatitis B from liver tissue samples. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[111]  H. Shiraha,et al.  M1903 Hepatitis B Virus DNA in Liver Tissue and Risk for Hepatocarcinogenesis in Patients with Hepatitis C Virus-Related Chronic Liver Disease: A Prospective Study , 2008 .

[112]  J. Hoofnagle,et al.  Systematic Review: The Effect of Preventive Lamivudine on Hepatitis B Reactivation during Chemotherapy , 2008, Annals of Internal Medicine.

[113]  D. Shouval.  What is the clinical significance of the high prevalence of occult hepatitis B in US liver transplant patients with chronic hepatitis C? , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[114]  A. Lok,et al.  Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[115]  H. Shiraha,et al.  Hepatitis B Virus DNA in Liver Tissue and Risk for Hepatocarcinogenesis in Patients with Hepatitis C Virus-Related Chronic Liver Disease , 2008, Intervirology.

[116]  J. Tanaka,et al.  Minimum infectious dose of hepatitis B virus in chimpanzees and difference in the dynamics of viremia between genotype A and genotype C , 2007, Transfusion.

[117]  N. Berhe,et al.  Intensity of Schistosoma mansoni, hepatitis B, age, and sex predict levels of hepatic periportal thickening/fibrosis (PPT/F): a large-scale community-based study in Ethiopia. , 2007, The American journal of tropical medicine and hygiene.

[118]  P. M. Mulrooney-Cousins,et al.  Persistent occult hepatitis B virus infection: experimental findings and clinical implications. , 2007, World journal of gastroenterology.

[119]  M. Massari,et al.  Analysis of occult hepatitis B virus infection in liver tissue of HIV patients with chronic hepatitis C , 2007, AIDS.

[120]  G. Raimondo,et al.  Disease progression and liver cancer in the ferroportin disease , 2007, Gut.

[121]  M. Torbenson,et al.  Liver enzyme flares and occult hepatitis B in persons with chronic hepatitis C infection. , 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[122]  W. Yung,et al.  Fatal reactivation of hepatitis B with temozolomide. , 2007, The New England journal of medicine.

[123]  D. Shouval,et al.  Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies , 2007, British journal of haematology.

[124]  Joon-Yong Park,et al.  Prevalence of occult HBV infection among subjects with normal serum ALT levels in Korea. , 2007, The Journal of infection.

[125]  M. Levrero,et al.  Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma , 2007, Hepatology.

[126]  G. Raimondo,et al.  Occult hepatitis B virus infection. , 2007, Journal of hepatology.

[127]  R. Bruno,et al.  Prophylaxis and treatment of hepatitis B in immunocompromised patients. , 2007, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[128]  Victor V. Keasler,et al.  Enhancement of Hepatitis B Virus Replication by the Regulatory X Protein In Vitro and In Vivo , 2006, Journal of Virology.

[129]  M. Yuen,et al.  Quantification of hepatitis B virus covalently closed circular DNA in patients with hepatocellular carcinoma. , 2006, Journal of hepatology.

[130]  M. Choti,et al.  Hepatitis C and hepatitis B nucleic acids are present in intrahepatic cholangiocarcinomas from the United States. , 2006, Human pathology.

[131]  S. Kenney,et al.  Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. , 2006, Cancer research.

[132]  G. Fattovich,et al.  Southern Europe as an example of interaction between various environmental factors: a systematic review of the epidemiologic evidence , 2006, Oncogene.

[133]  G. Raimondo,et al.  Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients , 2006, Cancer.

[134]  M. Levrero,et al.  Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. , 2006, Gastroenterology.

[135]  A. Mert,et al.  Prevalence of Occult Hepatitis B and Hepatitis C Virus Infections in Turkish Hemodialysis Patients , 2006, Renal failure.

[136]  Yoshiyuki Suzuki,et al.  Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. , 2006, The American journal of medicine.

[137]  E. Iannitto,et al.  High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma. , 2006, Haematologica.

[138]  C. Manegold,et al.  Functional analysis of hepatitis B virus reactivating in hepatitis B surface antigen‐negative individuals , 2005, Hepatology.

[139]  W. Au,et al.  Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. , 2005, Journal of hepatology.

[140]  P. Messa,et al.  Occult hepatitis B virus infection in dialysis patients: a multicentre survey , 2005, Alimentary pharmacology & therapeutics.

[141]  L. T. Krug,et al.  The targeting of primary effusion lymphoma cells for apoptosis by inducing lytic replication of human herpesvirus 8 while blocking virus production. , 2005, Blood.

[142]  L. Nicolle,et al.  Occult hepatitis B virus infection in a North American community-based population. , 2005, Journal of hepatology.

[143]  G. Raimondo,et al.  Hepatitis B virus and hepatitis C virus co-infection: additive players in chronic liver disease? , 2005, Annals of hepatology.

[144]  M. Asaka,et al.  Progressive Disappearance of Anti-Hepatitis B Surface Antigen Antibody and Reverse Seroconversion after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Previous Hepatitis B Virus Infection , 2005, Transplantation.

[145]  E. Iannitto,et al.  Hepatitis B virus reactivation and alemtuzumab therapy , 2005, European journal of haematology.

[146]  F. Zoulim.  New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. , 2005, Journal of hepatology.

[147]  G. Raimondo,et al.  What is the clinical impact of occult hepatitis B virus infection? , 2005, The Lancet.

[148]  H. Zentgraf,et al.  Hepatitis B virus genome is organized into nucleosomes in the nucleus of the infected cell , 1994, Virus Genes.

[149]  M. Opravil,et al.  Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only , 2005, European Journal of Clinical Microbiology and Infectious Diseases.

[150]  E. Buratti,et al.  Influence of RNA Secondary Structure on the Pre-mRNA Splicing Process , 2004, Molecular and Cellular Biology.

[151]  Christian Bréchot,et al.  Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. , 2004, Gastroenterology.

[152]  B. Nayak,et al.  Occult hepatitis B virus infection in chronic liver disease: full-length genome and analysis of mutant surface promoter. , 2004, Gastroenterology.

[153]  F. Zoulim,et al.  Cloning and expression of surface antigens from occult chronic hepatitis B virus infections and their recognition by commercial detection assays , 2004, Journal of medical virology.

[154]  F. Liprandi,et al.  Molecular and serological evaluation of surface antigen negative hepatitis B virus infection in blood donors from Venezuela , 2004, Journal of medical virology.

[155]  C. Siu,et al.  HBsAg seroclearance in chronic hepatitis B in the Chinese: Virological, histological, and clinical aspects , 2004, Hepatology.

[156]  K. Hayashi,et al.  Prevalence and clinical implications of occult hepatitis B viral infection in hemophilia patients in Japan , 2004, Journal of medical virology.

[157]  C. Gibbs,et al.  Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. , 2004, Gastroenterology.

[158]  J. Wands,et al.  Modulation of Hepatitis B Virus Secretion by Naturally Occurring Mutations in the S Gene , 2004, Journal of Virology.

[159]  D. Trono,et al.  Inhibition of Hepatitis B Virus Replication by APOBEC3G , 2004, Science.

[160]  D. Ganem,et al.  Hepatitis B virus infection--natural history and clinical consequences. , 2004, The New England journal of medicine.

[161]  D. Vlahov,et al.  High prevalence of occult hepatitis B in Baltimore injection drug users , 2004, Hepatology.

[162]  C. Tiribelli,et al.  Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. , 2004, Gastroenterology.

[163]  M. Omura,et al.  Long‐term histologic and virologic outcomes of acute self‐limited hepatitis B , 2003, Hepatology.

[164]  C-F Kao,et al.  Mechanisms for Inhibition of Hepatitis B Virus Gene Expression and Replication by Hepatitis C Virus Core Protein* , 2003, The Journal of Biological Chemistry.

[165]  R. Repp,et al.  Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein. , 2002, Journal of hepatology.

[166]  C. Chu,et al.  Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. , 2002, Gastroenterology.

[167]  M. Torbenson,et al.  Occult hepatitis B. , 2002, The Lancet. Infectious diseases.

[168]  Gail M. Williams,et al.  Current concepts - Schistosomiasis , 2002 .

[169]  G. Lau,et al.  Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen–negative Chinese carriers , 2001, Hepatology.

[170]  M. Manns,et al.  Structural organization of the hepatitis B virus minichromosome. , 2001, Journal of molecular biology.

[171]  M. Chevallier,et al.  High incidence of hepatitis B infections among chronic hepatitis cases of unknown aetiology. , 2001, Journal of hepatology.

[172]  F. Chisari,et al.  Noncytolytic control of viral infections by the innate and adaptive immune response. , 2001, Annual review of immunology.

[173]  K. Kidd‐Ljunggren,et al.  Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation. , 2000, Journal of hepatology.

[174]  F. Chisari,et al.  Inhibition of Hepatitis B Virus Replication during Schistosoma mansoni Infection in Transgenic Mice , 2000, The Journal of experimental medicine.

[175]  G. Raimondo,et al.  Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. , 1999, The New England journal of medicine.

[176]  Tomasz P. Michalak,et al.  Occult lifelong persistence of infectious hepadnavirus and residual liver inflammation in woodchucks convalescent from acute viral hepatitis , 1999, Hepatology.

[177]  A. Mason,et al.  Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen , 1998, Hepatology.

[178]  K. Koike,et al.  Persistent viremia after recovery from self‐limited acute hepatitis B , 1998, Hepatology.

[179]  L. Mimms,et al.  The prevalence of surface antigen variants of hepatitis B virus in Papua New Guinea, South Africa, and Sardinia , 1997, Hepatology.

[180]  P. Winch,et al.  The prevalence of hepatitis B and C infections among immigrants to a newly reclaimed area endemic for Schistosoma mansoni in Sinai, Egypt. , 1997, Acta tropica.

[181]  F. Chisari,et al.  The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T–lymphocyte response , 1996, Nature Medicine.

[182]  F. Chisari,et al.  Long-lasting memory T cell responses following self-limited acute hepatitis B. , 1996, The Journal of clinical investigation.

[183]  F. Chisari,et al.  Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. , 1996, Immunity.

[184]  S. Locarnini,et al.  The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes , 1995, Journal of virology.

[185]  S. Chen,et al.  Modulation of the trans-suppression activity of hepatitis C virus core protein by phosphorylation , 1995, Journal of virology.

[186]  H. Okamoto,et al.  Naturally occurring escape mutants of hepatitis B virus with various mutations in the S gene in carriers seropositive for antibody to hepatitis B surface antigen , 1994, Journal of virology.

[187]  L. Ferrell,et al.  "Occult" hepatitis B virus as source of infection in liver transplant recipients , 1994, The Lancet.

[188]  F. Chisari,et al.  Hepatitis B virus persistence after recovery from acute viral hepatitis. , 1994, The Journal of clinical investigation.

[189]  B. Tennant,et al.  Hepatocellular carcinoma in woodchuck hepatitis virus‐infected woodchucks: Presence of viral DNA in tumor tissue from chronic carriers and animals serologically recovered from acute infections , 1989, Hepatology.

[190]  R. Purcell,et al.  Detection of serum hepatitis B virus DNA in patients with chronic hepatitis using the polymerase chain reaction assay. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[191]  C. Bréchot,et al.  TRANSMISSION OF HEPATITIS B FROM HEPATITIS-B-SERONEGATIVE SUBJECTS , 1988, The Lancet.

[192]  P. Marion.  Ground Squirrel Hepatitis Virus , 1988 .

[193]  R. Burk,et al.  Hepatitis B virus DNA contains a glucocorticoid-responsive element. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[194]  D. Shafritz,et al.  Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. , 1981, The New England journal of medicine.

[195]  C. Bréchot,et al.  State of hepatitis B virus DNA in hepatocytes of patients with hepatitis B surface antigen-positive and -negative liver diseases. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[196]  Laura H. Smallwood,et al.  Studies of Donors Who Transmit Posttransfusion Hepatitis , 1979, Transfusion.

[197]  J. Hoofnagle,et al.  Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. , 1978, The New England journal of medicine.

[198]  J. Wands,et al.  Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. , 1975, Gastroenterology.

[199]  G. Keele.  Letter: Rubella vaccination. , 1973, Lancet.

[200]  L. Belloni.  [Morgagni-Réaumur correspondence in the Public Library of Forli]. , 1972, Gesnerus.